Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.79 |
| ▸ | NPC1 | O15118 | 6/20 | 0.79 |
| ▸ | MEN1 | O00255 | 6/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.79 |
| ▸ | MAPT | P10636 | 5/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.79 |
| ▸ | POLB | P06746 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.79 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.79 |
| ▸ | RELA | Q04206 | 1/20 | 0.79 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18851316 | 0.91 | RAB9A (0.67) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL4917891 | 0.89 | MEN1 (0.72) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL4924519 | 0.88 | RAB9A (0.79) | RAB9ANPC1MEN1KMT2AMAPT | |
| Frentizole SCHEMBL599582 | 0.88 | RAB9A (1.00) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL210774 | 0.87 | RAB9A (0.81) | RAB9ANPC1MEN1KMT2AMAPT | |
| Frentizole SCHEMBL11433152 | 0.87 | RAB9A (0.98) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL24104691 | 0.86 | KDM4E (0.74) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL30136366 | 0.86 | KDM4E (0.74) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL2759504 | 0.86 | RAB9A (0.76) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL4909124 | 0.85 | RAB9A (0.74) | RAB9ANPC1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335429-A1 | MOLECULAR GLUE AND SALL4 DEGRADER | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-10-10 | — | — | US | claimed |
| EP-4380557-A2 | MOLECULAR GLUE AND SALL4 DEGRADER | National University of Singapore (SG) | 2024-06-12 | — | — | EP | claimed |
| WO-2023014296-A2 | MOLECULAR GLUE AND SALL4 DEGRADER | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-02-09 | — | — | WO | claimed |
| US-20210380547-A1 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-12-09 | — | — | US | claimed |
| WO-2020079184-A2 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-04-23 | — | — | WO | claimed |
| EP-1680431-A1 | BENZOTHIAZOLE AND THIAZOLE'5,5-B!PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | claimed |
| WO-2005037845-A1 | BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| US-20240335429-A1 | MOLECULAR GLUE AND SALL4 DEGRADER | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-10-10 | — | — | US | disclosed |
| CN-113271941-B | Urea derivatives for the treatment and/or prophylaxis of cancer | 法国国家科学研究中心 | 2024-09-20 | — | — | CN | disclosed |
| EP-4380557-A2 | MOLECULAR GLUE AND SALL4 DEGRADER | National University of Singapore (SG) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023014296-A2 | MOLECULAR GLUE AND SALL4 DEGRADER | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-02-09 | — | — | WO | disclosed |
| US-20210380547-A1 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-12-09 | — | — | US | disclosed |
| WO-2020079184-A2 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-04-23 | — | — | WO | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005037845-A1 | BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335429-A1 | MOLECULAR GLUE AND SALL4 DEGRADER | SALL4, SAV1, SUMO1 | RAB9A 2386/4885NPC1 3795/4885MEN1 574/4885 |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | UBQLN1, UBE2T, NEDD4 | RAB9A 3792/4885NPC1 1713/4885MEN1 3866/4885 |
| US-20210380547-A1 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CXCR1, CXCR2, CXCR6 | RAB9A 1386/4885NPC1 331/4885MEN1 422/4885 |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | UBQLN1, NEDD4, UCHL5 | RAB9A 3771/4885NPC1 3462/4885MEN1 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.